WCLC 2020: Patritumab Deruxtecan treats NSCLC patients with EGFR mutations

Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths worldwide, of which 80 to 85 per cent are classified as non-small cell lung cancer (NSCLC).
for patients with metastasis, the prognosis is particularly poor, as only 6 to 10 per cent survive more than five years after being diagnosed.
About 25 to 30 percent of lung cancer worldwide has EGFR mutations, and it is estimated that about 83 percent of all NSCLC tumors have high expression of HER3 protein, which may be associated with increased metastasis, reduced survival, and standard drug resistance.
there is currently no anti-NSCLC therapy targeting HER3.
recently, The First Third Phase of the Japanese pharmaceutical company announced that its Phase I study targeting her3 antibody drug coupled (ADC) patritumab deruxtecan for the treatment of EGFR mutation non-small cell lung cancer has yielded partial results.
results were published at the 2020 World Lung Cancer Congress (WCLC).
this exploratory analysis evaluated 56 NSCLC patients who were resistant to EGFR inhibitors.
the expression of HER3 with an H score, which is a method of assessing the percentage of tumor cells through cell membrane staining.
results showed that almost all assessable patients had high levels of HER3 at baseline, with a medium H score of 180 (range: 2-280).
the results showed that patients who responded to the treatment of patritumab deruxtecan had higher her3 expression levels at baseline.